Facebook Twitter Linkedin Google Plus

New Hybrid Cancer Center Model Helps Meet the Demand for Better Quality Care

New Hybrid Cancer Center Model Helps Meet the Demand for Better Quality Care +

A new cancer center model is helping meet the demand for better quality cancer care in community settings. Hybrid academic-community cancer centers began emerging and evolving at several sites in some southern and mid-Atlantic states during the last several years, and in February 2017 a number of their directors, and other key members of their respective institutions, gathered for a CME-sponsored full-day workshop in Miami to share experiences and best practices to advance the model.

Read more

Interim Phase II Results with Sacituzumab Govitecan in Pretreated Metastatic Urothelial Cancer Shows Confirmed Objective Response Rate (ORR) of 34%

Interim Phase II Results with Sacituzumab Govitecan in Pretreated Metastatic Urothelial Cancer Shows Confirmed  Objective Response Rate (ORR) of 34% +

Results from an interim Phase II study with sacituzumab govitecan (IMMU-132) shows that the investigational agent is active in patients with metastatic urothelial cancer (mUC) who have relapsed or are refractory to chemotherapies and immune checkpoint inhibitors or IOs.

Read more

ASH 2016: Highlighting Clinically Useful Information

ASH 2016: Highlighting Clinically Useful Information +

The upcoming 58th annual meeting of the American Society of Hematology, to be held in San Diego, CA, December 3 - 6, will be overflowing with interesting, informative, and clinically useful news and valuable research updates. The annual meeting is considered the world's premier event in malignant and non-malignant hematology and provides an invaluable educational experience and an opportunity to review thousands of scientific abstracts highlighting updates in the latest topics in hematology. The annual meeting also offers a great opportunity to network with top minds in the field, as well as a global community of more than 20,000 hematology professionals from every subspecialty.

Read more

ASCO 2017: Evaluating the Combination of Nivolumab + Brentuximab Vedotin inRelapsed Hodgkin Lymphoma

ASCO 2017: Evaluating the Combination of Nivolumab + Brentuximab Vedotin inRelapsed Hodgkin Lymphoma +

A pivotal trial, planned for mid-2017, will evaluate the combination of brentuximab vedotin and nivolumab versus brentuximab vedotin alone as a potential treatment option for patients with relapsed/refractory or transplant-ineligible advanced classical Hodgkin lymphoma.

Read more

News


View all

Editorial


View all


Latest Articles


View all

Expert Interview


View all

Must Read Articles


View all

How to Contribute

Featured Events


View all events


Newsletter sign up

To subscribe to our weekly newsletter please send us your email address...


Lonza

Go to top

ADC Review
is made possible by:

Stay in touch

Facebook Twitter Linkedin Google Plus

Skip to toolbar